Wall Street snapped a two-week losing streak as headlines about President Donald Trump's remarks on tariff policy, economic data on inflation and corporate earnings took center stage. The January U.S.

Leerink Partnrs upgraded shares of CVS Health (NYSE:CVS – Free Report) from a hold rating to a strong-buy rating in a ...

CVS Health (NYSE:CVS – Free Report) had its target price increased by Wolfe Research from 67.00 to 70.00 in a report ...

Shares of CVS Health Corporation (NYSE: CVS) experienced a jolt, rising over 15% on February 12, 2025, as the market responded to the release of its fourth-quarter 2024 earnings report. CVS Health's ...

Full Year 2024 Results Key Financial Results Revenue: US$372.8b (up 4.5% from FY 2023).

CVS Health downgraded to Hold due to political risks, declining cash flow, and industry battles despite strong Q4 sales and a ...

CVS Health Corp issued an optimistic guidance for 2025 stemming from the expected recovery in its insurance business — Aetna's turnaround.

CVS Health CVS turned in solid fourth-quarter results, and its 2025 guidance for 6%-11% adjusted EPS growth without any share ...

Asian markets closed mostly higher on Wednesday, with Japan's Nikkei 225 gaining 0.42%, China's Shanghai Composite Index ...

CVS appears uniquely positioned to improve health outcomes, and we appreciate management's focus on better leveraging its assets through digital and other means to bring a more consumer-centric ...

The earnings surpassed analyst expectations with an adjusted earnings per share (EPS) of $1.19, beating estimates of $0.91 by ...

CEO David Joyner highlighted the company's Q4 adjusted EPS of $1.19 and adjusted operating income of $2.7 billion. He introduced 2025 adjusted EPS guidance of $5.75 to $6.00, emphasizing recovery in ...